Compare PFS & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFS | IRON |
|---|---|---|
| Founded | 1839 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | PFS | IRON |
|---|---|---|
| Price | $22.98 | $71.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $23.25 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 1.0M | 522.9K |
| Earning Date | 01-27-2026 | 02-27-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | ★ 112.38 | N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $866,820,000.00 | N/A |
| Revenue This Year | $1.11 | N/A |
| Revenue Next Year | $7.44 | N/A |
| P/E Ratio | $10.43 | ★ N/A |
| Revenue Growth | ★ 42.77 | N/A |
| 52 Week Low | $14.34 | $30.82 |
| 52 Week High | $23.98 | $99.50 |
| Indicator | PFS | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 39.57 |
| Support Level | $20.28 | $72.61 |
| Resistance Level | $23.98 | $83.93 |
| Average True Range (ATR) | 0.70 | 4.28 |
| MACD | 0.07 | -0.49 |
| Stochastic Oscillator | 72.02 | 11.63 |
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.